Clinical Trial

Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator

Study acronym: OPT-BB WOMEN
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2024 (before its estimated September 2024 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this pilot study is to document the percentage achievement in effective HR control (average nighttime HR \< 70 bpm) during WCD use in a cohort of female patients with cardiomyopathy in an outpatient setting using continuous heart rate (HR) trends data from the WCD to optimize BB/ivabradine dosage, as compared to a prior historical control.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT04504188
Lead Sponsor Zoll Medical Corporation
Conditions Cardiomyopathies, Heart Failure
Enrollment 300 participants
Start Date 2021-03-08
Primary Completion 2024-09 (estimated)
Study Completion 2024-12 (estimated)
Updated on ClinicalTrials.gov 2024-07-24